Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Trial ID or NCT#

NCT06088290

Status

recruiting iconRECRUITING

Purpose

The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.

Official Title

Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Minggui Pan, MD, PhD
Minggui Pan, MD, PhD
Medical oncologist, Sarcoma specialist
Clinical Professor, Medicine - Oncology
Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)
Nam Quoc Bui
Nam Quoc Bui
Medical oncologist, Sarcoma specialist
Clinical Associate Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

Gaston Federico Boggio, M.D.
+34 91 823 4524

SEND MESSAGE

View on ClinicalTrials.gov